Cargando…
Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
Newly emerging Omicron subvariants continue to emerge around the world, presenting potential challenges to current vaccination strategies. This study investigates the extent of neutralizing antibody escape by new subvariants XBB.1.5, CH.1.1, and CA.3.1, as well as their impacts on spike protein biol...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882202/ https://www.ncbi.nlm.nih.gov/pubmed/36711991 http://dx.doi.org/10.1101/2023.01.16.524244 |
_version_ | 1784879254087925760 |
---|---|
author | Qu, Panke Faraone, Julia N. Evans, John P. Zheng, Yi-Min Carlin, Claire Anghelina, Mirela Stevens, Patrick Fernandez, Soledad Jones, Daniel Panchal, Ashish Saif, Linda J. Oltz, Eugene M. Xu, Kai Gumina, Richard J. Liu, Shan-Lu |
author_facet | Qu, Panke Faraone, Julia N. Evans, John P. Zheng, Yi-Min Carlin, Claire Anghelina, Mirela Stevens, Patrick Fernandez, Soledad Jones, Daniel Panchal, Ashish Saif, Linda J. Oltz, Eugene M. Xu, Kai Gumina, Richard J. Liu, Shan-Lu |
author_sort | Qu, Panke |
collection | PubMed |
description | Newly emerging Omicron subvariants continue to emerge around the world, presenting potential challenges to current vaccination strategies. This study investigates the extent of neutralizing antibody escape by new subvariants XBB.1.5, CH.1.1, and CA.3.1, as well as their impacts on spike protein biology. Our results demonstrated a nearly complete escape of these variants from neutralizing antibodies stimulated by three doses of mRNA vaccine, but neutralization was rescued by a bivalent booster. However, CH.1.1 and CA.3.1 variants were highly resistant to both monovalent and bivalent mRNA vaccinations. We also assessed neutralization by sera from individuals infected during the BA.4/5 wave of infection and observed similar trends of immune escape. In these cohorts, XBB.1.5 did not exhibit enhanced neutralization resistance over the recently dominant BQ.1.1 variant. Notably, the spike proteins of XBB.1.5, CH.1.1, and CA.3.1 all exhibited increased fusogenicity compared to BA.2, correlating with enhanced S processing. Overall, our results support the administration of new bivalent mRNA vaccines, especially in fighting against newly emerged Omicron subvariants, as well as the need for continued surveillance of Omicron subvariants. |
format | Online Article Text |
id | pubmed-9882202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-98822022023-01-28 Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants Qu, Panke Faraone, Julia N. Evans, John P. Zheng, Yi-Min Carlin, Claire Anghelina, Mirela Stevens, Patrick Fernandez, Soledad Jones, Daniel Panchal, Ashish Saif, Linda J. Oltz, Eugene M. Xu, Kai Gumina, Richard J. Liu, Shan-Lu bioRxiv Article Newly emerging Omicron subvariants continue to emerge around the world, presenting potential challenges to current vaccination strategies. This study investigates the extent of neutralizing antibody escape by new subvariants XBB.1.5, CH.1.1, and CA.3.1, as well as their impacts on spike protein biology. Our results demonstrated a nearly complete escape of these variants from neutralizing antibodies stimulated by three doses of mRNA vaccine, but neutralization was rescued by a bivalent booster. However, CH.1.1 and CA.3.1 variants were highly resistant to both monovalent and bivalent mRNA vaccinations. We also assessed neutralization by sera from individuals infected during the BA.4/5 wave of infection and observed similar trends of immune escape. In these cohorts, XBB.1.5 did not exhibit enhanced neutralization resistance over the recently dominant BQ.1.1 variant. Notably, the spike proteins of XBB.1.5, CH.1.1, and CA.3.1 all exhibited increased fusogenicity compared to BA.2, correlating with enhanced S processing. Overall, our results support the administration of new bivalent mRNA vaccines, especially in fighting against newly emerged Omicron subvariants, as well as the need for continued surveillance of Omicron subvariants. Cold Spring Harbor Laboratory 2023-01-17 /pmc/articles/PMC9882202/ /pubmed/36711991 http://dx.doi.org/10.1101/2023.01.16.524244 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Qu, Panke Faraone, Julia N. Evans, John P. Zheng, Yi-Min Carlin, Claire Anghelina, Mirela Stevens, Patrick Fernandez, Soledad Jones, Daniel Panchal, Ashish Saif, Linda J. Oltz, Eugene M. Xu, Kai Gumina, Richard J. Liu, Shan-Lu Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants |
title | Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants |
title_full | Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants |
title_fullStr | Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants |
title_full_unstemmed | Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants |
title_short | Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants |
title_sort | extraordinary evasion of neutralizing antibody response by omicron xbb.1.5, ch.1.1 and ca.3.1 variants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882202/ https://www.ncbi.nlm.nih.gov/pubmed/36711991 http://dx.doi.org/10.1101/2023.01.16.524244 |
work_keys_str_mv | AT qupanke extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT faraonejulian extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT evansjohnp extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT zhengyimin extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT carlinclaire extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT anghelinamirela extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT stevenspatrick extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT fernandezsoledad extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT jonesdaniel extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT panchalashish extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT saiflindaj extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT oltzeugenem extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT xukai extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT guminarichardj extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants AT liushanlu extraordinaryevasionofneutralizingantibodyresponsebyomicronxbb15ch11andca31variants |